Access to the PPM Journal and newsletters is FREE for clinicians.
10 Articles in Volume 13, Issue #4
Traumatic Brain Injury
US Service Members With Polytrauma
Cancer Patient: Controlling The Pain
Pharmaceutical Treatment of the Cancer Pain Patient
Drug Interactions in Cancer Patients Requiring Concomitant Chemotherapy and Analgesics
How Do We Get Enough Physicians to Medically Manage The Difficult (High-dose Opioid) Pain Patient?
Ultra-high Dose Opioid Therapy: Uncommon and Declining, But Still Needed
Head Trauma: More Than A Headache
Ask the Expert May 2013
Letters to the Editor May 2013

Cancer Patient: Controlling The Pain

National and international organizations have attempted to develop guidelines to facilitate compassionate and effective cancer pain management systems, including the WHO analgesic ladder.

Clinical guidance for the treatment of cancer pain has been established by the National Comprehensive Cancer Network1 and the American Pain Society.2 Both organizations emphasize that clinicians should provide a comprehensive pain assessment to identify the etiology of each patient's pain. The World Health Organization (WHO) analgesic ladder3 developed in 1986, provided an important schematic at a time when it was well recognized that cancer pain was grossly undertreated.4,5 Even today many oncologists turn to the WHO analgesic guidelines for some schematic approach to treating pain (Figure 1).

For mild to moderate pain, patients will generally be managed with non-opioids (or non-scheduled opioids, depending on the state) such as acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), tramadol, or other adjunctive medications. Together with physical therapy, heat/cold therapy, and various modalities, these are the first step in the ladder. For moderate to severe pain, patients may be managed with schedule III opioids (generally considered to be "mild" or "weaker" opioids) such as buprenorphine, codeine, or hydrocodone, usually combined with acetaminophen or an NSAID. Morphine, hydromorphone, oxycodone, oxymorphone, methadone, and fentanyl are generally considered to be "strong" opioids (Table 1). More correctly stated, none of these opioids are "strong" or "weak," because their activity is a function of opioid-binding affinity, potency, opioid receptor physiology, and polymorphic differences. In short, a "weak" opioid in one patient may very well be a "strong" opioid in another, and visa versa.6

Read more on the Pharmaceutical Treatment of the Cancer Pain Patient.

Last updated on: June 25, 2015
Continue Reading:
Pharmaceutical Treatment of the Cancer Pain Patient

Join The Conversation

Register or Log-in to Join the Conversation
close X